Minimal residual disease detection and evolved IGH clones analysis in acute b lymphoblastic leukemia using IGH deep sequencing

Frontiers in Immunology

Volumn 7, Issue OCT, 2016, Pages

  Wu, Jinghua ^a   Jia, Shan ^b   Wang, Changxi ^a   Zhang, Wei ^a   Liu, Sixi ^b   Zeng, Xiaojing ^a   Mai, Huirong ^b   Yuan, Xiuli ^b   Du, Yuanping ^a   Wang, Xiaodong ^b   Hong, Xueyu ^a   Li, Xuemei ^a   Wen, Feiqiu ^b   Xu, Xun ^a   Pan, Jianhua ^c   Li, Changgang ^b   Liu, Xiao ^a,d  

^a BGI SHENZHEN   (China)

^b SHENZHEN CHILDREN'S HOSPITAL   (China)

^c Shenzhen Children's Hospital ^*  (China)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute B lymphoblast leukemia; High throughput sequencing; IGH, clonal evolution; Minimal residual disease

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; T LYMPHOCYTE RECEPTOR;

ARTICLE; CHILD; DISEASE COURSE; FLOW CYTOMETRY; FOLLOW UP; GENE; GENETIC ANALYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN; IGH GENE; IMMUNOPHENOTYPING; LYMPHATIC LEUKEMIA; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 84997284732     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00403     Document Type: Article

References (46)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev (2010) 36(4):277-85. doi:10.1016/j.ctrv.2010.02.003.
2. Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol (2015) 16(4):465-74. doi:10.1016/S1470-2045(15)70082-3.
3. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 118(8):2077-84. doi:10.1182/blood-2011-03-338707.
4. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 352(9142):1731-8. doi:10.1016/S0140-6736(98)04058-6.
5. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood (2008) 111(12):5477-85. doi:10.1182/blood-2008-01-132837.
6. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2010) 2010:7-12. doi:10.1182/asheducation-2010.1.7.
7. Szczepanski T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol (2002) 15(1):37-57. doi:10.1053/beha.2002.0184.
8. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood (2010) 115(23):4657-63. doi:10.1182/blood-2009-11-253435.
9. din-Cinar SA, Can Kucuksezer U, Deniz G. Implications of minimal residual disease by flow cytometry in pediatric acute leukemias. Int Trends Immunity (2013) 1(4):54-61.
10. Roshal M, Fromm JR, Winter S, Dunsmore K, Wood BL. Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytometry B Clin Cytom (2010) 78(3):139-46. doi:10.1002/cyto.b.20511.
11. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia (2005) 19(1):49-56. doi:10.1038/sj.leu.2403559.
12. Forestier E, Johansson B, Borgstrom G, Kerndrup G, Johansson J, Heim S. Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. The NOPHO Leukemia Cytogenetic Study Group. Eur J Haematol (2000) 64(3):194-200. doi:10.1034/j.1600-0609.2000.90103.x.
13. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia (2003) 17(6):1013-34. doi:10.1038/sj.leu.2402922.
14. van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 21(4):706-13. doi:10.1038/sj.leu.2404535.
15. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica (2005) 90(3):382-90.
16. Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med (2012) 4(134):134ra63. doi:10.1126/scitranslmed.3003656.
17. Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res (2014) 20(17):4540-8. doi:10.1158/1078-0432.CCR-13-3231.
18. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 120(26):5173-80. doi:10.1182/blood-2012-07-444042.
19. Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica (2007) 92(5):605-11. doi:10.3324/haematol.10432.
20. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood (2002) 100(7):2399-402. doi:10.1182/blood-2002-04-1130.
21. Cillo C, Dick JE, Ling V, Hill RP. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res (1987) 47(10):2604-8.
22. Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene (2013) 32(2):135-40. doi:10.1038/onc.2012.48.
23. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol (2015) 16(7):766-74. doi:10.1038/ni.3160.
24. Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood (2012) 120(22):4407-17. doi:10.1182/blood-2012-05-429811.
25. Zhang W, Du Y, Su Z, Wang C, Zeng X, Zhang R, et al. IMonitor: a robust pipeline for TCR and BCR repertoire analysis. Genetics (2015) 201(2):459-72. doi:10.1534/genetics.115.176735.
26. Baker KE, Parker R. Nonsense-mediated mRNA decay: terminating erroneous gene expression. Curr Opin Cell Biol (2004) 16(3):293-9. doi:10.1016/j.ceb.2004.03.003.
27. Khajavi M, Inoue K, Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet (2006) 14(10):1074-81. doi:10.1038/sj.ejhg.5201649.
28. Hoffmann R, Seidl T, Neeb M, Rolink A, Melchers F. Changes in gene expression profiles in developing B cells of murine bone marrow. Genome Res (2002) 12(1):98-111. doi:10.1101/gr.201501.
29. Bashford-Rogers RJ, Nicolaou KA, Bartram J, Goulden NJ, Loizou L, Koumas L, et al. Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse. Leukemia (2016). doi:10.1038/leu.2016.142.
30. Tonegawa S. Somatic generation of antibody diversity. Nature (1983) 302(5909):575-81. doi:10.1038/302575a0.
31. Darlow JM, Stott DI. V(H) replacement in rearranged immunoglobulin genes. Immunology (2005) 114(2):155-65. doi:10.1111/j.1365-2567.2004.02084.x.
32. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med (1990) 323(7):448-55. doi:10.1056/NEJM199008163230705.
33. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia (2008) 22(4):771-82. doi:10.1038/leu.2008.5.
34. Weinstein JA, Jiang N, White RA III, Fisher DS, Quake SR. High-throughput sequencing of the zebrafish antibody repertoire. Science (2009) 324(5928):807-10. doi:10.1126/science.1170020.
35. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood (2009) 114(19):4099-107. doi:10.1182/blood-2009-04-217604.
36. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med (2009) 1(12):12ra23. doi:10.1126/scitranslmed.3000540.
37. Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, et al. Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. J Mol Diagn (2009) 11(3):194-200. doi:10.2353/jmoldx.2009.080047.
38. Davi F, Faili A, Gritti C, Blanc C, Laurent C, Sutton L, et al. Early onset of immunoglobulin heavy chain gene rearrangements in normal human bone marrow CD34 + cells. Blood (1997) 90(10):4014-21.
39. LeBien TW. Fates of human B-cell precursors. Blood (2000) 96(1):9-23.
40. Hendriks RW, Middendorp S. The pre-BCR checkpoint as a cell-autonomous proliferation switch. Trends Immunol (2004) 25(5):249-56. doi:10.1016/j.it.2004.02.011.
41. Martensson IL, Almqvist N, Grimsholm O, Bernardi AI. The pre-B cell receptor checkpoint. FEBS Lett (2010) 584(12):2572-9. doi:10.1016/j.febslet.2010.04.057.
42. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, et al. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med (2004) 199(5):673-85. doi:10.1084/jem.20031637.
43. Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, et al. The pre B cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia (2015) 29(8):1623-31. doi:10.1038/leu.2015.113.
44. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol (2013) 13(8):578-91. doi:10.1038/nri3487.
45. Buchner M, Swaminathan S, Chen Z, Muschen M. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. Immunol Rev (2015) 263(1):192-209. doi:10.1111/imr.12235.
46. Gawad C, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc Natl Acad Sci U S A (2014) 111(50):17947-52. doi:10.1073/pnas.1420822111.